Michael Burkes Brophy Sells 602 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 602 shares of Natera stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $113,145.90. Following the completion of the transaction, the chief financial officer owned 70,109 shares in the company, valued at $13,176,986.55. This trade represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, September 30th, Michael Burkes Brophy sold 2,491 shares of Natera stock. The shares were sold at an average price of $162.05, for a total value of $403,666.55.
• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The shares were sold at an average price of $137.40, for a total value of $418,383.00.
• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $282,276.39.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $139.50, for a total value of $105,322.50.

Natera Trading Up 3.7%

Shares of NTRA stock opened at $195.00 on Friday. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $196.63. The company has a market capitalization of $26.76 billion, a P/E ratio of -102.09 and a beta of 1.74. The business’s 50 day moving average is $170.70 and its two-hundred day moving average is $159.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter last year, the firm earned ($0.30) earnings per share. The firm’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after acquiring an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Natera by 7.0% in the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after acquiring an additional 166,768 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Natera by 13.7% in the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after acquiring an additional 245,719 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on NTRA. Canaccord Genuity Group restated a “buy” rating and issued a $200.00 price target on shares of Natera in a research note on Tuesday, October 14th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Morgan Stanley restated an “overweight” rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Stephens restated an “overweight” rating and issued a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Finally, Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $197.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.